Abstract:Sorafenib has become the standard therapy for patients with advanced hepatocellular carcinoma (HCC). Unfortunately, most patients eventually develop acquired resistance. Therefore, it is important to identify potential biomarkers that could predict the efficacy of sorafenib. To identify target proteins associated with the development of sorafenib resistance, we applied stable isotope labelling with amino acids in cell culture (SILAC)-based quantitative proteomic approach to analyze differences in protein expression levels between parental HuH-7 and sorafenib-acquired resistance HuH-7 (HuH-7R) cells in vitro, combined with an isobaric tags for relative and absolute quantitation (iTRAQ) quantitative analysis of HuH-7 and HuH-7R tumors in vivo. In total, 2,450 quantified proteins were identified in common in SILAC and iTRAQ experiments, with 81 showing increased expression (>2.0-fold) with sorafenib resistance and 75 showing decreased expression (<0.5-fold). In silico analyses of these differentially expressed proteins predicted that 10 proteins were related to cancer with involvements in cell adhesion, migration, and invasion. Knockdown of one of these candidate proteins, galectin-1, decreased cell proliferation and metastasis in HuH-7R cells and restored sensitivity to sorafenib. We verified galectin-1 as a predictive marker of sorafenib resistance and a downstream target of the AKT/mTOR/HIF-1α signaling pathway. In addition, increased galectin-1 expression in HCC patients' serum was associated with poor tumor control and low response rate. We also found that a high serum galectin-1 level was an independent factor associated with poor progression-free survival and overall survival. In conclusion, these results suggest that galectin-1 is a possible biomarker for predicting the response of HCC patients to treatment with sorafenib. As such, it may assist in the stratification of HCC and help direct personalized therapy.

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK|[sol]|PI3K|[sol]|AKT signaling

Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis

Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (itraq) Quantitative Proteomic Analysis Identifies Galectin-1 As a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer*

Expression of Galectin-1 in Carcinoma-Associated Fibroblasts Promotes Gastric Cancer Cell Invasion Through Upregulation of Integrin Beta 1

Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts

ST6GALNAC4 Promotes Hepatocellular Carcinogenesis by Inducing Abnormal Glycosylation.

Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma

Galectin-1 Overexpression Promotes Progression and Chemoresistance to Cisplatin in Epithelial Ovarian Cancer

Autophagy Drives Galectin-1 Secretion From Tumor-Associated Macrophages Facilitating Hepatocellular Carcinoma Progression

Galectin-1-Induced Autophagy Facilitates Cisplatin Resistance of Hepatocellular Carcinoma

Galectin-1 mediates TGF-β-induced transformation from normal fibroblasts into carcinoma-associated fibroblasts and promotes tumor progression in gastric cancer.

Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk

Downregulation of Galectin-3 Causes A Decrease in Upar Levels and Inhibits the Proliferation, Migration and Invasion of Hepatocellular Carcinoma Cells

Overexpression of Galectin‐1 is Associated with Poor Prognosis in Human Hepatocellular Carcinoma Following Resection

GJA1 Promotes Hepatocellular Carcinoma Progression by Mediating TGF-β-induced Activation and the Epithelial–mesenchymal Transition of Hepatic Stellate Cells

Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex

Long noncoding RNA lncGALM increases risk of liver metastasis in gallbladder cancer through facilitating N‐cadherin and IL‐1β‐dependent liver arrest and tumor extravasation

GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway

Galectin-1 overexpression induces normal fibroblasts translate into cancer-associated fibroblasts and attenuates the sensitivity of anlotinib in lung cancer

GSTA1/CTNNB1 Axis Facilitates Sorafenib Resistance Via Suppressing Ferroptosis in Hepatocellular Carcinoma